April 7, 2016

TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: NICOLE COPELAND, PROTOCOL SECTION

DATE: APRIL 7, 2016

RE: PROTOCOL GOG-0218 – DO NOT TERMINATE

Protocol Title: “A PHASE III TRIAL OF CARBOPLATIN AND PACLITAXEL PLUS PLACEBO VERSUS CARBOPLATIN AND PACLITAXEL PLUS CONCURRENT BEVACIZUMAB (NSC #704865, IND #113912) FOLLOWED BY PLACEBO, VERSUS CARBOPLATIN AND PACLITAXEL PLUS CONCURRENT AND EXTENDED BEVACIZUMAB, IN WOMEN WITH NEWLY DIAGNOSED, PREVIOUSLY UNTREATED, STAGE III OR IV, EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCER. NCI-SUPPLIED AGENT(S): BEVACIZUMAB/ PLACEBO (NSC #704865, IND #113912)”

NCI Version December 17, 2014

Study Chair: Robert A. Burger, MD; (215) 746-4043; Robert.burger@uphs.upenn.edu

Protocol GOG-0218 termination notice was posted in error.

Please continue to submit follow-up data as we track long-term survivors.

If your site has no patients in follow-up and your IRB allows data submission in response to Queries on previously submitted data, your site can close out this study with your IRB.

If your site has patients in follow-up, please keep this study open with your IRB.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Unsubscribe